UTV Reports on CV6-168’s Progress Toward First Human Trials
In November 2022, UTV reported on CV6 Therapeutics’ preparations to advance CV6-168 into its first human clinical trial. Designed to work alongside standard cancer therapies, the investigational drug was being developed for a Phase 1a study to assess safety, dosing and how it is processed by the body. The article also highlights CV6’s move from California to Belfast following an invitation from Professor Paddy Johnston, and the support provided by Queen’s University Belfast, QUBIS and Invest Northern Ireland.
Read the full article on ITV News / UTV.
Image: Robert Ladner, Founder and CEO of CV6 Therapeutics; Ian Greer, QUB President and Vice Chancellor; Brian McCaul, CEO at QUBIS. Photo Credit: MCE Public Relations
More News
View all
CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial
CV6 Therapeutics (‘CV6’), announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work.
Fierce Pharma’s Spotlight on CV6 and Northern Ireland Life Sciences
The feature follows CV6’s move from California to Belfast and the investment supporting CV6-168’s development toward clinical trials.